Metabolomics, the study of metabolites, the small-molecule end products of metabolism collectively known as the metabolome, provides the full picture of a biological system enabling a deep understanding of health, disease, and treatment response, whether influenced by genes, the environment, epigenetics or the microbiome.
Metabolon’s proprietary untargeted metabolomics platform reveals biological insights otherwise unseen. Leveraging one of the world’s most diverse and rich metabolomics data sets, Metabolon sets the standard in metabolomics and accelerates research and product development in every sector from pharma and agriculture to consumer products and wellness, as well as population health and academia.
Metabolon’s approach sets the standard of 4Cs for performance: Coverage, Competency, Comparability and Capacity for the most complete picture. The unmatched depth provides functional metabolite understanding fueling deep insights enabling our clients to accelerate research and product development success in the pharma, population health, consumer products, agriculture, wellness and academic research sectors.
Metabolon offers a range of metabolomics service offerings that support and advance research at every stage. Wherever you are in your research and development journey, our team of experts will work with you to clearly define your goals and develop a customized plan to meet them. We offer applications throughout the drug discovery and preclinical development continuum and product lifecycle.
Metabolomics is a revolutionary technology for obtaining a comprehensive picture of the metabolome and mapping metabolites to their key biochemical pathways. It helps answer a wide variety of research questions and gives crucial insight into the function of genes, the basis of disease, and how treatments work. It can also identify associated biomarkers, making it an attractive tool for investigators across multiple applications.
Many laboratories have metabolite profiling or analytical chemistry capabilities, but none have the technology and workflow that allow Metabolon to produce the most comprehensive, high-quality and accurate metabolomics data available. Our unique bioinformatics infrastructure and data interpretation experience transform that data into knowledge that you can immediately put into action.
Metabolon offers a range of metabolomics service offerings that support and advance research at every stage. Whether you want to survey the entire metabolome, only complex lipids, or just a few key pathways or metabolites, our team of experts will work with you to clearly define your goals and develop a customized plan to meet them.
Metabolomics applications for the drug discovery and preclinical phases are many.
See above (Metabolomics)
See above (Metabolomics)
Our expertise and institutional knowledge clear this barrier through interpretation services led by our Ph.D. scientists and access to bioinformatics tools that enable you to explore the data.
Lipidomics is a more focused form of metabolomics that surveys complex lipids. Our Complex Lipid Panel is the only lipidomics method able to provide absolute quantitation, molecular species concentration and complete fatty acid composition of each covered lipid class. This unique method covers more than 1100 molecular species across 16 lipid classes, including principle phospholipid sphingolipid and neutral lipid classes.
Targeted assays and panels focus on a specific metabolite or metabolites and can be used to track biomarkers and improve biological understanding in both clinical and preclinical research. They are an excellent tool for rapidly and accurately establishing pharmacodynamics, translational studies, gauging efficacy and safety in clinical trials and for post-market surveillance studies. The role of biomarkers is also expanding to inform new indications and targets, patient segmentation and novel mechanisms of action. Metabolon’s targeted metabolite assays provide precise measurements of metabolites in a wide variety of sample matrices. Metabolites can be valuable biomarkers because they are sensitive to specific enzyme inhibitors and signaling pathways (e.g. kinase inhibitors) and are associated with many diseases such as metabolic disorders and cancer. LC-MS/MS-based assays offer unique advantages over legacy assay platforms such as ELISA or IHC. Assays can be customized based on your needs and developed for research use only (RUO) or validated under Good Clinical Practice (GCP) and Clinical Laboratory Improvement Amendments (CLIA). Select from an ever-expanding, diverse menu of more than 150 pre-developed assays (qualified and /or validated) involving more than 250 metabolites for research or clinical trial use, including a fatty acid panel, short-chain fatty acid (SCFA) panel, bile acid panel and amino acid panel, such as:
Metabolomics applications for the drug discovery and preclinical phases are many.
Metabolomics applications for the drug discovery and preclinical phases are many.
Metabolon, Inc. has not received any reviews.
Metabolon, Inc. has not received any endorsements.